

Special Issue

Treatment of Dystonia with Botulinum Toxins

Message from the Guest Editors

The treatment of focal dystonia has been revolutionized by botulinum toxins. First approved in 1989 by the US Food and Drug Administration, botulinum toxin injection is now the worldwide mainstay therapy for this often painful and disabling condition. There are several safe and effective botulinum toxins, and more are under development. This Special Issue of *Toxins* focuses on treatment of the different focal dystonias and provides an overview of available botulinum products and relevant practice guidelines. Included in this Special Issue are in-depth discussions of the treatment of cervical dystonia, blepharospasm, oromandibular dystonia, task specific dystonia, and other limb dystonias.

Guest Editors

Prof. David Charles

Vanderbilt University Medical Center, 1161 21st Avenue South, Suite A-1106 MCN, Nashville, TN 37232, USA

Prof. Peter Hedera

Vanderbilt University Medical Center, 1161 21st Avenue South, Suite A-1106 MCN, Nashville, TN 37232, USA

Deadline for manuscript submissions

closed (28 February 2020)



Toxins

an Open Access Journal
by MDPI

Impact Factor 4.0
CiteScore 8.2
Indexed in PubMed



mdpi.com/si/29357

Toxins
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
toxins@mdpi.com

[mdpi.com/journal/
toxins](https://mdpi.com/journal/toxins)





Toxins

an Open Access Journal
by MDPI

Impact Factor 4.0
CiteScore 8.2
Indexed in PubMed



[mdpi.com/journal/
toxins](https://mdpi.com/journal/toxins)



About the Journal

Message from the Editor-in-Chief

Toxinology is an incredibly diverse area of study, ranging from field surveys of environmental toxins to the study of toxin action at the molecular level. The editorial board and staff of *Toxins* are dedicated to providing a timely, peer-reviewed outlet for exciting, innovative primary research articles and concise, informative reviews from investigators in the myriad of disciplines contributing to our knowledge on toxins. We are committed to meeting the needs of the toxin research community by offering useful and timely reviews of all manuscripts submitted. Please consider *Toxins* when submitting your work for publication.

Editor-in-Chief

Prof. Dr. Jay Fox

Department of Microbiology, University of Virginia, Charlottesville, VA,
USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Toxicology) / CiteScore - Q1 (Toxicology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).